Your browser doesn't support javascript.
loading
Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease.
Bowen, Ellen R; DiGiacomo, Phillip; Fraser, Hannah P; Guttenplan, Kevin; Smith, Benjamin A H; Heberling, Marlene L; Vidano, Laura; Shah, Nigam; Shamloo, Mehrdad; Wilson, Jennifer L; Grimes, Kevin V.
Afiliação
  • Bowen ER; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • DiGiacomo P; Weill Cornell Medicine, New York, NY, USA.
  • Fraser HP; University of Michigan Medical School, Ann Arbor, MI, USA.
  • Guttenplan K; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Smith BAH; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Heberling ML; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Vidano L; Vollum Institute, Oregon Health & Science University, Portland, OR, USA.
  • Shah N; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Shamloo M; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Wilson JL; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Grimes KV; Center for Biomedical Informatics Research, Stanford School of Medicine, Stanford, CA, USA.
Discov Ment Health ; 3(1): 27, 2023 Nov 30.
Article em En | MEDLINE | ID: mdl-38036718
Schizophrenia is a debilitating condition necessitating more efficacious therapies. Previous studies suggested that schizophrenia development is associated with aberrant synaptic pruning by glial cells. We pursued an interdisciplinary approach to understand whether therapeutic reduction in glial cell-specifically astrocytic-phagocytosis might benefit neuropsychiatric patients. We discovered that beta-2 adrenergic receptor (ADRB2) agonists reduced phagocytosis using a high-throughput, phenotypic screen of over 3200 compounds in primary human fetal astrocytes. We used protein interaction pathways analysis to associate ADRB2, to schizophrenia and endocytosis. We demonstrated that patients with a pediatric exposure to salmeterol, an ADRB2 agonist, had reduced in-patient psychiatry visits using a novel observational study in the electronic health record. We used a mouse model of inflammatory neurodegenerative disease and measured changes in proteins associated with endocytosis and vesicle-mediated transport after ADRB2 agonism. These results provide substantial rationale for clinical consideration of ADRB2 agonists as possible therapies for patients with schizophrenia.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Discov Ment Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Discov Ment Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça